Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oncolytic virus
Biotech
Replimune to lay off staff after 'disappointing' second rejection
Even with additional data and a new team of reviewers, the FDA still found fault with the trials for Replimune's oncolytic virus.
Darren Incorvaia
Apr 10, 2026 1:56pm
Candel glows with $100M RTW deal to fund cancer drug launch
Feb 20, 2026 4:04am
Replimune's request for melanoma approval rejected by FDA
Jul 22, 2025 8:45am
Theriva prioritizes oncolytic adenovirus at expense of GvHD drug
Mar 7, 2025 4:47am
4 years on from launch, IconOVir sells oncolytic virus to UroGen
Feb 20, 2025 9:12am
Candel burns bright as phase 3 cancer win sends stock up 200%
Dec 11, 2024 9:49am
